Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2031250398) titled 'A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia' on Sept. 30.
Study Type: Interventional
Study Design:
randomized controlled trial, double blind, placebo control, parallel assignment, treatment purpose
Primary Sponsor: Tsunoda Takeshi
Condition:
Schizophrenia
Intervention:
SEP-363856 (75 and 100 mg/day) or placebo
Recruitment Status: Not Recruiting
Phase: 3
Date of First Enrollment: 01/11/2025
Target Sample Size: 522
Countries of Recruitment:
The United States
Japan
To know more, visit https://jrct.mhlw.go.jp/latest-detail/jRCT2031250398
P...